Oziltus Injection, Solution
Product Images NDC 70121-2701

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Oziltus (NDC 70121-2701). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Oziltus Denosumab Mobz Injection 1)

A line graph depicting corrected calcium levels (mmol/L and mg/dL) over a 57-day study period for 23 subjects receiving Denosumab 120 mg. The graph shows a decreasing trend in calcium levels from baseline to about day 8, followed by fluctuating but generally stable levels thereafter. Sample sizes at each time point are indicated below the x-axis.*

FDA Label Image

Carton (Oziltus Denosumab Mobz Injection 2)

Packaging label for Oziltus (denosumab-mobz) Injection, containing 120 mg/1.7 mL (70 mg/mL) solution. This human prescription drug is for subcutaneous use only, supplied as a single-dose vial with no preservative. Manufactured by Amneal Pharmaceuticals LLC, the label includes usage instructions and storage conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.